Ligands with its PDB code and its tanimoto calculated from the molecule, present in the database, which has for MMscode: MMs03297565
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
---|---|---|---|---|---|
Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
HTF | N-(2-OXOTETRAHYDROFURAN-3-YL)OCTANAMIDE | A | 2AVX | 0.73 | |
RO4 | [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL- BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER | A | 2TCL | 0.77 | |
SB1 | (21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA- 2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE | A,B | 1FKI | 0.75 | |
REZ | (2R)-2-AMINO-7-{[(1R)-1-CARBOXYETHYL]AMINO}- 7-OXOHEPTANOIC ACID | A,B | 2J9P | 0.72 | |
REZ | (2R)-2-AMINO-7-{[(1R)-1-CARBOXYETHYL]AMINO}- 7-OXOHEPTANOIC ACID | A,B,C,D | 2VGK | 0.72 | |
U17 | METHYL N-[(2S,3R)-3-AMINO-2-HYDROXYHEPTANOYL]- L-SERYL-L-LEUCINATE | A | 2GGB | 0.74 | |
REY | GLYCYL-L-ALPHA-AMINO-EPSILON-PIMELYL- D-ALANINE | A | 1IKI | 0.75 | |
IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A | 3EMY | 0.71 | |
IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A | 2H6T | 0.71 | |
IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A,B | 1LS5 | 0.71 | |
IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A,B | 1SME | 0.71 | |
IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A,C | 1W6I | 0.71 | |
IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A,B | 1XDH | 0.71 | |
IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A,B | 2QZX | 0.71 | |
IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A | 1IZE | 0.71 | |
IHN | N-(3-methylbutanoyl)-L-valyl-N- [(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)- 2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)- 1-methyl-2-oxoethyl]amino}-2-hydroxy- 1-(2-methylpropyl)-4-oxobutyl]- L-valinamide | A,B | 1M43 | 0.71 | |
IGN | {[(1R)-2-((2S)-2-{[(3-{[AMINO(IMINO)METHYL]AMINO}PROPYL)AMINO]CARBONYL}PIPERIDINYL)- 1-(CYCLOHEXYLMETHYL)-2-OXOETHYL]AMINO}ACETIC ACID | A | 1K1O | 0.75 | |
IGN | {[(1R)-2-((2S)-2-{[(3-{[AMINO(IMINO)METHYL]AMINO}PROPYL)AMINO]CARBONYL}PIPERIDINYL)- 1-(CYCLOHEXYLMETHYL)-2-OXOETHYL]AMINO}ACETIC ACID | H,I | 1K21 | 0.75 | |
S80 | N1-HYDROXY-2-(3-HYDROXY-PROPYL)- 3-ISOBUTYL-N4-[1-(2-METHOXY-ETHYL)- 2-OXO-AZEPAN-3-YL]-SUCCINAMIDE | A,B | 1BIW | 0.71 | |
AR9 | (2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7- dimethyl-3,15-dioxo-1,4-diazacyclopentadecan- 5-yl]-4-hydroxy-2-methylbutanamide | A,B,C | 3DV1 | 0.74 | |
H2A | (6R,7R)-3-[(ACETYLOXY)METHYL]-7- {[(6S)-6-(GLYCYLAMINO)-7-OXIDO- 7-OXOHEPTANOYL]AMINO}-8-OXO-5-THIA- 1-AZABICYCLO[4.2.0]OCTANE-2-CARBOXYLATE | A | 1PW8 | 0.73 | |
OHN | N-3-OXO-DODECANOYL-L-HOMOSERINE LACTONE | E,F,G,H | 2UV0 | 0.72 | |
LAE | 3-OXO-OCTANOIC ACID (2-OXO-TETRAHYDRO- FURAN-3-YL)-AMIDE | A,B,C,D | 1L3L | 0.7 | |
LAE | 3-OXO-OCTANOIC ACID (2-OXO-TETRAHYDRO- FURAN-3-YL)-AMIDE | A,B | 2Q0O | 0.7 | |
ABX | 5-[1-(ACETYLAMINO)-3-METHYLBUTYL]- 4-(METHOXYCARBONYL)PROLINE | A | 1XOE | 0.71 | |
IVS | 3-HYDROXY-6-METHYL-4-(3-METHYL- 2-(3-METHYL-2-(3-METHYL-BUTYRYLAMINO)- BUTYRYLAMINO)-BUTYRYLAMINO)-HEPTANOIC ACID ETHYL ESTER | A,B | 1ME6 | 0.75 | |
EPX | EPOXOMICIN | D,F,G,H,I,K, L,N,Y | 1G65 | 0.7 | |
Y11 | N-[(1S)-2-[(4-cyano-1-methylpiperidin- 4-yl)amino]-1-(cyclohexylmethyl)- 2-oxoethyl]morpholine-4-carboxamide | A,B | 2R9M | 0.76 | |
DH9 | (2S,3S,5S)-5-[(N-FORMYL-L-LEUCYL)OXY]- 2-HEXYL-3-HYDROXYHEXADECANOIC ACID | A,B | 2PX6 | 0.7 | |
RE1 | GLYCYL-L-A-AMINOPIMELYL-E-(D-2- AMINOETHYL)PHOSPHONATE | A | 1MPL | 0.7 | |
REX | GLYCYL-L-ALPHA-AMINO-EPSILON-PIMELYL- D-ALANYL-D-ALANINE | A | 1IKG | 0.74 |